Rini BI, et al : The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Advanced Renal Cell Carcinoma (RCC). J Immunother Cancer 7 : 354, 2019
Motzer RJ, et al : Nivolumab Plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 378 : 1277-1290, 2018
Rini BI, et al : Pembrolizumab Plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380: 1116-1127, 2019
Motzer RJ, et al : Avelumab Plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380: 1103-1115, 2019
Hodi FS, et al : Nivolumab Plus Ipilimumab or Nivolumab Alone versus Ipilimumab Alone in Advanced Melanoma (CheckMate 067) : 4-Year Outcomes of a Multicentre, Randomised, Phase 3 Trial. Lancet Oncol 19 : 1480-1492, 2018